论文部分内容阅读
目的探讨阿替普酶治疗急性缺血性脑卒中(AIS)的疗效和影响预后的因素。方法回顾性分析68例阿替普酶治疗AIS患者的临床资料,判断其疗效并采用Logistic回归分析影响预后的危险因素。结果依据改良Rankin量表评分评价,预后良好39例(57.4%),预后不良29例(42.6%)。Logistic回归分析显示糖尿病、溶栓后收缩压、溶栓前血糖、美国国立卫生研究院卒中量表(NIHSS)评分和高同型半胱氨酸(Hcy)是影响溶栓治疗预后的危险因素。结论阿替普酶治疗AIS有效,糖尿病、溶栓前血糖、NIHSS评分、溶栓后收缩压和高Hcy是影响预后的危险因素。
Objective To investigate the therapeutic effect of alteplase on acute ischemic stroke (AIS) and its prognostic factors. Methods A retrospective analysis of 68 cases of alteplase in patients with AIS clinical data to determine its efficacy and the use of Logistic regression analysis of prognostic risk factors. Results According to the modified Rankin scale, the prognosis was good in 39 cases (57.4%) and poor prognosis in 29 cases (42.6%). Logistic regression analysis showed that diabetes, thrombolysis systolic blood pressure, blood glucose before thrombolysis, NIH Stroke Scale (NIHSS) and homocysteine (Hcy) were risk factors influencing the prognosis of thrombolytic therapy. Conclusion Alteplase treatment of AIS, diabetes, pre-thrombolysis, NIHSS score, systolic blood pressure after thrombolysis and high Hcy risk factors affecting the prognosis.